Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 11 , ISSUE 3 ( July-September, 2022 ) > List of Articles

Original Article

Post-COVID Mucormycosis: A Retrospective Observational Study

Nurani Shaik, Akhila Bollam, Gayathri Konduri, Aedula Vinaya Sekhar

Keywords : Amphotericin B, COVID, diabetes mellitus, posaconazole, postcoronavirus disease 2019 mucormycosis

Citation Information : Shaik N, Bollam A, Konduri G, Sekhar AV. Post-COVID Mucormycosis: A Retrospective Observational Study. Indian J Respir Care 2022; 11 (3):230-233.

DOI: 10.4103/ijrc.ijrc_26_22

License: CC BY-NC-SA 4.0

Published Online: 01-12-2022

Copyright Statement:  Copyright © 2022; Indian Journal of Respiratory Care.


Introduction: Mucormycosis is a life.threatening fungal infection caused by fungi belonging to the family Mucorales, and the fungus mainly responsible for infection in humans is Rhizopus oryzae. Recently, several cases of coronavirus disease 2019 (COVID-19).associated mucormycosis are being reported worldwide. Subjects and Methods: A retrospective observational study was conducted in the emergency department at a tertiary care hospital for 2 months. The primary objectives of this study were to assess the risk factors of post COVID-19 the signs and symptoms, toassess the relationship between steroidal usage and post-COVID-19 mucormycosis evaluating the treatment patterns. Results and Discussion: In the current study, 45 cases were examined. It was found that patients with comorbidities, especially diabetes mellitus, i.e., 80%, have more exposure to post-COVID-19 mucormycosis than any other comorbidity. It is also found that methylprednisolone is the major steroid used, accounting for 43% of the steroids used for the treatment of COVID. The treatment included the usage of lipophilic amphotericin B in 61% of the patients, which is associated with lipophilic posaconazole in 95% of the patients. Conclusion: Post-COVID-19 mucormycosis is a major threat to the individuals affected with COVID-19. The major risk factor is the presence of diabetes mellitus; therefore, proper measures must be undertaken in diabetic patients. Patient develops any symptoms related to the eyes, nose, face, lungs, and skin should seek a medical emergency to avoid chronic complications.

  1. Jagtap SV, Jagtap SS, Nagar V, Varshney K. Invasive mucormycosis in post COVID 19 infections: Case report with review. IP cytology and histopathology research 2021;6:135-9.
  2. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020;12:e10726.
  3. Ibrahim A, Spellberg B, Edwards J Jr. Iron acquisition: A novel prospective on mucormycosis pathogenesis and treatment. Infec dic 2008;21:620-5.
  4. Agnihotri AK, Vij M, Aruoma OI, Yagnik VD, Bahorun T, Villamil ME, et al. The Double Trouble: COVID-19 Associated Mucormycosis a Focused Review and Future Perspectives. Glob J Med Pharm Biomed Update 2021;16:4.
  5. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel) 2019;5:26.
  6. RamaSwami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D, et al. COVID-19 associated mucormycosis presenting to the emergency department – An observational study of 70 patients. An International Journal of Medicine 2021;114:464-70.
  7. Soman R, Sunavala A. Post COVID-19 mucormycosis – From the frying pan into the fire. J Assoc Physicians India 2021;69:13-4.
  8. Desai EJ, Pandya A, Upadhya I, Patel T, Banerjee S, Jain V. Epidemiology, clinical features and management of rhino orbital mucormycosis in post COVID 19 patients. Indian J Otolaryngol Head Neck Surg 2022;74:103-7.
  9. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146.
  10. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994;39:3-22.
  11. Ferry AP, Abedi S. Diagnosis and management of rhino-orbitocerebral mucormycosis (phycomycosis). A report of 16 personally observed cases. Ophthalmology 1983;90:1096-104.
  12. Mishra N, Mutya VS, Thomas A, Rai G, Reddy B, Anithakumari AM, et al. A case series of invasive mucormycosis in patients with COVID19 infection. Int J Otorhinolaryngol Head Neck Surg 2021;7:867-70.
  13. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr., Ibrahim AS. Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis 2009;48:1743-51.
  14. Banerjee M, Pal R, Bhadada SK. Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgraduate medical journal, postgradmedj-2021-140537. 2021. Advance online publication.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.